Clinical features of multisystem inflammatory syndrome in children
| العنوان: | Clinical features of multisystem inflammatory syndrome in children |
|---|---|
| المؤلفون: | Jordan E Roberts, Lauren A. Henderson |
| المصدر: | Curr Opin Rheumatol |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, Myocarditis, Coronavirus disease 2019 (COVID-19), SARS-CoV-2, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Mucocutaneous zone, COVID-19, Mucocutaneous Lymph Node Syndrome, medicine.disease, Article, Systemic Inflammatory Response Syndrome, Rheumatology, Shock (circulatory), Adjunctive treatment, Humans, Medicine, Kawasaki disease, Decompensation, medicine.symptom, business, Intensive care medicine |
| الوصف: | Purpose of review To review diagnosis, clinical characteristics and treatment of multisystem inflammatory syndrome in children (MIS-C) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent findings MIS-C emerged in spring 2020 as a hyperinflammatory syndrome following SARS-CoV-2 exposure in children. Despite growing awareness of MIS-C, diagnosis remains challenging due to the range of phenotypes and severity. Fever accompanied by shock, cardiac dysfunction, gastrointestinal symptoms, or mucocutaneous signs suggestive of Kawasaki disease, especially in the presence of known or suspected coronavirus disease 2019 exposure, should trigger consideration of MIS-C. However, clinical presentations are highly varied and may overlap with other infectious diseases. Clinicians must maintain a high index of suspicion for MIS-C and be aware that patients may develop coronary artery aneurysms and myocarditis even with few or no Kawasaki disease symptoms. More precise diagnostic criteria and specific biomarkers are needed to aid diagnosis. Intravenous immunoglobulin (IVIG) is first-line therapy, and steroids should be considered as initial adjunctive treatment for patients with severe manifestations or other risk factors. Prompt treatment is essential, as patients may worsen acutely, though overall prognosis is reassuring. Summary MIS-C associated with SARS-CoV-2 has varied clinical manifestations. Clinicians must be aware of the common presentation and potential for decompensation and cardiac sequalae to guide appropriate evaluation and treatment. |
| تدمد: | 1531-6963 1040-8711 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2978f1f1177b1261dd4bad567905a9a5 https://doi.org/10.1097/bor.0000000000000818 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....2978f1f1177b1261dd4bad567905a9a5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15316963 10408711 |
|---|